STREAMING NOW: Watch Now

Early data shows promising results from Regeneron's antibody cocktail for coronavirus

Biotechnology company Regeneron released some early results of tests using its antibody cocktail in coronavirus patients Tuesday, and said it seemed to reduc...

Posted: Sep 29, 2020 4:43 PM
Updated: Sep 29, 2020 8:00 PM

Biotechnology company Regeneron released some early results of tests using its antibody cocktail in coronavirus patients Tuesday, and said it seemed to reduce levels of the virus and improve symptoms in patients.

The greatest improvements were seen in patients who hadn't already mounted a natural response to the infection, the company said.

The results only involve 275 patients of the 1,000 they have enrolled in this particular trial, but appear 'very promising,' Dr. Jeanne Marrazzo, the director of the division of infectious diseases at University of Alabama at Birmingham, told CNN.

The treatment also showed positive trends at reducing medical visits for the patients, none of whom were sick enough to be hospitalized at the start of the trial, the company said. The numbers in this early release of information were small and the data has not been peer reviewed yet. Only topline data was available in a news release from the company.

A company spokesperson said the data validates the treatment as a therapeutic substitute for a natural response to the virus.

Marrazzo said what stood out to her is that the study characterized patients by their immune responses prior to treatment and determined who did and did not benefit.

'What I think is fascinating is that it shows that antibodies really matter and the antibody to the spike protein was really helpful, particularly when people made the antibodies themselves,' said Marrazzo. 'Whether it's antibody therapy or vaccine that target these proteins, it sounds like we are on the right track. I think that's really encouraging.'

She was also encouraged by the reduction in the amount of virus in people's throats, which could in theory reduce the risk of infecting others. 'If it plays out and you could treat people early and actually reduce the viral load in the nasopharynx, and they might be less infectious, that would be hugely helpful,' said Marrazzo.

Because the company released the information in a news release and not as a scientific report, it's unclear who was enrolled in the study and how reflective they were of the population. The treatment would have to be tested in many more people to know for sure how well it works. Scientists will also want to know more about how many patients who got the treatment needed to be hospitalized.

'We don't have that information today, but we will,' Dr. Leonard Schleifer, co-founder of Regeneron, told CNN. 'We have already learned that hospitalized patients have even higher viral load, suggesting they're not attempting an adequate immune response. So we would hope we'd be able to see the same thing with those patients.'

Schleifer is 'very encouraged' by these early results.

'It came in exactly the way we expected it to work,' Schleifer said.

Dr. Claudia Hoyen, an infectious disease specialist with University Hospitals Cleveland Medical Center, also sees the results as 'promising.' The data doesn't show any safety concerns, she said, and the preliminary data looks good so far.

'It seems safe, and it seems to be headed in the right direction in terms of decreasing the virologic load and, looks like there's some preliminary correlation with fewer symptoms and less hospitalizations,' Hoyen said. 'But again, they still have a lot of patients to get through to know for sure.'

Jennifer Gommerman, a professor of immunology at the University of Toronto, also used the phrase 'really promising.'

She said that, along with Regeneron's earlier work published in a peer-reviewed journal in August, the additional key takeaway is that the 'cocktail' approach is effective.

A cocktail antibody therapy uses two or more lab-engineered antibodies. Regeneron's cocktail includes a monoclonal antibody that targets the spike protein the virus uses to drill into healthy cells, and another antibody that targets a different part of the novel coronavirus. With two, the hope is is to trap and shut down viral replication.

'It appears that they've got positive results and that this antibody cocktail doses reduce the amount of time that the patients are sick, especially the patients that weren't able to mount their own antibody response,' Gommerman said. 'They're obviously going to have to do much more human experiments and bigger trials to really make sure.'

Dr. Richard Besser, a former acting CDC director who now heads the Robert Wood Johnson Foundation, said it makes sense that a treatment that gives a patient antibodies would help the immune system, but he said peer review will find any holes or pitfalls.

'I would withhold judgment on this until we see the data,' said Besser. 'You know these early results that keep coming out from companies in press releases strike me as being about much more, much more about the stock price than they are about science.'

Gommerman, Marrazzo and Hoyen think antibody treatments could be a real help in patient populations that don't generate a real robust immune response to a vaccine, like patients in nursing homes or other elderly people. The treatment may also be helpful in the transition period, before everyone can get vaccinated.

Regeneron isn't the only company working on an antibody treatment. Eli Lilly is also in late stage trials with its antibody treatment. There are at least 70 different antibody treatments under investigation according to BIO, an association that represents major biotechnology companies.

Regeneron said that there will be more data to come from this trial, from a trial involving hospitalized patients, and one that is testing the antibody cocktail as a prevention for people who have contact with someone in their household who has Covid-19.

Schleifer said Regeneron is in talks with regulators about these results to see if the US Food and Drug Administration would consider an emergency authorization of the drug. They have additional data the company will submit for formal approval.

Regeneron co-founder George Yancopoulous said during a call with shareholders Tuesday that it is up to regulators to decide if this is enough information to make this therapeutic intervention available sooner to patients who might need it.

'I think that this deserves to be discussed with regulatory authorities, because of all of the societal implications,' Yancopoulous said.

'We think that there's a lot of evidence here to suggest that this is a therapeutic solution that could really benefit quite a number of individuals and patients.'

Mississippi Coronavirus Cases

Data is updated nightly.

Cases: 309223

Reported Deaths: 7153
CountyCasesDeaths
DeSoto21005250
Hinds19989411
Harrison17590303
Rankin13388277
Jackson13169243
Madison9965212
Lee9900170
Jones8319161
Forrest7554149
Lauderdale7232237
Lowndes6306144
Lamar614685
Lafayette6081118
Washington5296133
Bolivar4778130
Oktibbeha458097
Panola4461103
Pearl River4447142
Warren4310119
Marshall4302103
Pontotoc417672
Monroe4063132
Union405175
Neshoba4009176
Lincoln3892109
Hancock373785
Leflore3471124
Sunflower332090
Tate325984
Pike3226105
Scott311973
Yazoo305369
Alcorn301566
Itawamba297977
Copiah294365
Coahoma290779
Simpson290486
Tippah285368
Prentiss276659
Marion266479
Leake262473
Wayne261541
Grenada257385
Covington255380
Adams247082
Newton246161
George238947
Winston226181
Tishomingo222867
Jasper220248
Attala213673
Chickasaw205857
Holmes187272
Clay183354
Stone179733
Clarke178177
Tallahatchie176240
Calhoun165632
Yalobusha160236
Smith159734
Walthall131143
Greene129633
Lawrence126823
Noxubee126634
Montgomery125842
Perry125238
Amite121041
Carroll121026
Webster113932
Jefferson Davis105932
Tunica103425
Claiborne101430
Benton97525
Kemper95728
Humphreys94732
Franklin83123
Quitman78916
Choctaw74417
Wilkinson65329
Jefferson64928
Sharkey49817
Issaquena1686
Unassigned00

Alabama Coronavirus Cases

Cases: 522512

Reported Deaths: 10790
CountyCasesDeaths
Jefferson755371494
Mobile39129799
Madison34124500
Tuscaloosa25408444
Montgomery24059573
Shelby23225242
Baldwin20730302
Lee15638166
Calhoun14358311
Morgan14171273
Etowah13705348
Marshall12012220
Houston10416279
Elmore10024203
Limestone9862148
Cullman9509191
St. Clair9486236
Lauderdale9280233
DeKalb8762183
Talladega8127173
Walker7151276
Autauga6763106
Jackson6762110
Blount6532133
Colbert6236132
Coffee5436113
Dale4781111
Russell431239
Franklin421382
Chilton4130110
Covington4069115
Tallapoosa3922148
Escambia390374
Dallas3528150
Chambers3519122
Clarke347360
Marion3076100
Pike306676
Lawrence296395
Winston273272
Bibb256761
Marengo248561
Geneva246475
Pickens233259
Barbour227155
Hale218675
Butler213268
Fayette209660
Henry188444
Cherokee182744
Randolph177841
Monroe173140
Washington165538
Macon156548
Clay150255
Crenshaw149557
Cleburne147041
Lamar140034
Lowndes137353
Wilcox124727
Bullock122040
Conecuh109728
Perry107726
Sumter103332
Coosa99428
Greene91434
Choctaw58824
Out of AL00
Unassigned00
Tupelo
Partly Cloudy
77° wxIcon
Hi: 76° Lo: 44°
Feels Like: 77°
Columbus
Clear
75° wxIcon
Hi: 76° Lo: 47°
Feels Like: 75°
Oxford
Partly Cloudy
72° wxIcon
Hi: 74° Lo: 40°
Feels Like: 72°
Starkville
Clear
73° wxIcon
Hi: 75° Lo: 45°
Feels Like: 73°
Sunshine should bring continued warmth into your Tuesday. But going into the night, a cold front approaches. This will bring a quick round of light to moderate showers overnight and a late-season frost that could damage or kill sensitive plants.
WTVA Radar
WTVA Temperatures
WTVA Severe Weather